Newsfile Corp · October 27, 2026

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

Get the app for more

Explore stock news, insights and company research.